DIPENTUM Drug Patent Profile
✉ Email this page to a colleague
When do Dipentum patents expire, and when can generic versions of Dipentum launch?
Dipentum is a drug marketed by Mylan Spclt Viatris and is included in one NDA.
The generic ingredient in DIPENTUM is olsalazine sodium. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the olsalazine sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DIPENTUM?
- What are the global sales for DIPENTUM?
- What is Average Wholesale Price for DIPENTUM?
Summary for DIPENTUM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Drug Prices: | Drug price information for DIPENTUM |
| What excipients (inactive ingredients) are in DIPENTUM? | DIPENTUM excipients list |
| DailyMed Link: | DIPENTUM at DailyMed |
Pharmacology for DIPENTUM
| Drug Class | Aminosalicylate |
US Patents and Regulatory Information for DIPENTUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Spclt Viatris | DIPENTUM | olsalazine sodium | CAPSULE;ORAL | 019715-001 | Jul 31, 1990 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DIPENTUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Spclt Viatris | DIPENTUM | olsalazine sodium | CAPSULE;ORAL | 019715-001 | Jul 31, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DIPENTUM
See the table below for patents covering DIPENTUM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 549237 | ⤷ Start Trial | |
| Australia | 6862481 | ⤷ Start Trial | |
| Canada | 1179602 | APPLICATION PHARMACOLOGIQUE DE L'ACIDE 3,3'-AZO-BIS- 6-HYDROXYBENZOIQUE ET COMPOSES PHARMACEUTIQUES LE CONTENANT (USE OF 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) AS A DRUG AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME) | ⤷ Start Trial |
| Germany | 3161216 | ⤷ Start Trial | |
| European Patent Office | 0036637 | USE OF 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) AS A DRUG AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ⤷ Start Trial |
| Israel | 62382 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) | ⤷ Start Trial |
| Japan | H0148247 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch